Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 500 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tarceva, erlotinib, OSI-774 Clear all
Completed Phase 2 Interventional

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

NCT00045526
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IV Esophageal Cancer
Interventions
erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Ipilimumab, Erlotinib, Crizotinib, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00600015
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Erlotinib + Sorafenib, Erlotinib + Placebo
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Fort Myers, Florida • Gainesville, Georgia • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

NCT00609804
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sorafenib, Erlotinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
16
States / cities
Fort Myers, Florida • Gainesville, Georgia • Marietta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 14, 2026, 2:32 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

NCT02099058
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Osimertinib, Nivolumab, Telisotuzumab vedotin, Erlotinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

NCT01174043
View directory record Official record
Conditions
Leukemia, Myelomonocytic, Acute
Interventions
Erlotinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 14, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

NCT01205685
View directory record Official record
Conditions
Hormone-sensitive Metastatic Breast Cancer
Interventions
OSI-906, Erlotinib, Letrozole, Goserelin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Franklin, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Oct 14, 2026, 2:32 AM EDT
Terminated Not applicable Interventional Results available

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

NCT00503841
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Drug · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

NCT01180959
View directory record Official record
Conditions
Liver Cancer
Interventions
Bevacizumab, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

NCT00553800
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab, Erlotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
70 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Galloway, New Jersey • Mount Holly, New Jersey • Paoli, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

NCT00998036
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Temsirolimus, Cisplatin, Erlotinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 14, 2026, 2:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

NCT01600807
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic
Interventions
Gemcitabine, Erlotinib, OSI-906, Gemcitabine, Erlotinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 14, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT00482625
View directory record Official record
Conditions
Intraductal Papillary Mucinous Neoplasm of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
erlotinib hydrochloride, conventional surgery, immunohistochemistry staining method, protein expression analysis, biopsy, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

NCT00068367
View directory record Official record
Conditions
Sarcoma
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
101
States / cities
Little Rock, Arkansas • Davis, California • Martinez, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

NCT00193154
View directory record Official record
Conditions
Kidney Cancer
Interventions
OSI-774, Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer

NCT00855894
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pertuzumab, Erlotinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Rancho Mirage, California • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

NCT00085553
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tipifarnib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 14, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

NCT00392665
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Bevacizumab, erlotinib, Sulindac
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

NCT00408499
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, erlotinib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors

NCT02014909
View directory record Official record
Conditions
Advanced Cancer
Interventions
KTN3379
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 14, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

NCT00063258
View directory record Official record
Conditions
Lung Cancer
Interventions
Tarceva (OSI-774), Paclitaxel, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 14, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca

NCT01555489
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
Ascorbic Acid
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 14, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT01248247
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, AZD6244, MK-2206, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 14, 2026, 2:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

NCT02152631
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Abemaciclib, Erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
54
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Duarte, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 2:32 AM EDT